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Abstract 
Globally, Prostate cancer (PCa) is the most frequently occurring non-cutaneous cancer, and is the 
second highest cause of cancer mortality in men. Serum prostate specific antigen (PSA) has been 
the standard in PCa screening since its approval by the American Food & Drug Administration 
(FDA) in 1994. Currently, PSA is used as an indicator for PCa - patients with a serum PSA level 
above 4ng/mL will often undergo prostate biopsy to confirm cancer. Unfortunately fewer than 
~30% of these men will biopsy positive for cancer, meaning that the majority of men undergo 
invasive biopsy with little benefit. Despite PSA’s notoriously poor specificity (33%), there is still a 
significant lack of credible alternatives. Therefore an ideal biomarker that can specifically detect 
PCa at an early stage is urgently required. The aim of this study was to investigate the potential of 
using deregulation of urinary proteins in order to detect Prostate Cancer (PCa) among Benign 
Prostatic Hyperplasia (BPH). To identify the protein signatures specific for PCa, protein expression 
profiling of 8 PCa patients, 12 BPH patients and 10 healthy males was carried out using LC-MS/MS. 
This was followed by validating relative expression levels of proteins present in urine among all the 
patients using quantitative real time-PCR. This was followed by validating relative expression levels 
of proteins present in urine among all the patients using quantitative real time-PCR. This approach 
revealed that significant the down-regulation of Fibronectin and TP53INP2 was a characteristic 
event among PCa patients. Fibronectin mRNA down-regulation, was identified as offering im-
proved specificity (50%) over PSA, albeit with a slightly lower although still acceptable sensitivity 
(75%) for detecting PCa. As for TP53INP2 on the other hand, its down-regulation was moderately 
sensitive (75%), identifying many patients with PCa, but was entirely non-specific (7%), designating 
many of the benign samples as malignant and being unable to accurately identify more than one 
negative. 
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Introduction 
Globally, PCa is the second most common, 
non-cutaneous cancer among men (1, 2). Various 
studies have observed a positive correlation between 
age and incidence of PCa (2, 3, 4). Environmental 
factors, particularly diet, have also been reported to 
potentially play a role in a man’s risk for PCa (5). A 
number of techniques are currently available for as-
sessing prostate health, the most common of which 
include digital rectal exam (DRE), trans-rectal ultra-
sonography (TRUS), and prostate specific anti-
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gen-based testing (PSA) (6, 7).  
Since PSA is primarily produced in the prostate 
and is therefore relatively prostate specific, it was 
proposed that a sharp but consistent increase in serum 
PSA was indicative of exponential prostate cell 
growth, as might occur in PCa (8). PSA test had been 
validated for detecting PCa using any serum level 
above the empirically determined cutoff of 4ng/mL 
(9). PSA’s use as a marker for PCa was soon limited by 
the many instances of BPH that were also associated 
with an increased serum PSA above the 4ng/mL cut-
off, and especially in the range of 4-10ng/mL (10).  
Serum PSA testing for the early detection of PCa 
has a sensitivity of around 86% and a specificity of 
approximately 33%, depending on patient's age and 
local prevalence of disease (11, 12). These problems 
have formed the basis for much controversy sur-
rounding PSA’s use as a regular blood-based screen-
ing tool for PCa (13, 14). As such, the search for novel 
PCa biomarkers, especially from non-invasive fluids, 
has been ongoing (15, 16). 
As a promising powerful biological research 
technology, proteomics has recently become a chief 
tool in the identification of disease biomarkers (12). 
One major advantage of proteomics is its ability to 
concurrently check the whole proteome or 
sub-proteomes such that differentially expressed or 
modified proteins corresponding to a disease condi-
tion can be identified. This enables researchers to 
merge several protein markers together to form pan-
els of protein markers with higher sensitivity and 
specificity for the detection and screening of a disease. 
Because a cancer proteome is an exceptionally com-
plex biological sample which contains information 
from almost all the biological activities that take place 
in cancer cells, cancer tissue microenvironment, and 
cancer cell-host interaction (17), 2D SDS-PAGE is not 
suitable as it is time-consuming, technically chal-
lenging, requires special concern to achieve tolerable 
comparability/reproducibility and is not ideal for the 
analysis of smaller polypeptides (<10 kDa) (18, 19). 
As an alternative to 2D SDS-PAGE, the shotgun 
proteomics “bottom-up approach” has evolved. 
Shotgun proteomics involve the proteolytic digestion 
of the protein into relatively small peptides whose 
m/z can be accurately determined by mass spec-
trometry. The generated peptides are then separated 
in one or more successive steps of liquid chromatog-
raphy, analyzed by tandem MS (MS/MS), and the 
information is processed with bioinformatic tools to 
obtain the protein composition of the original sample 
(20, 21). A major advantage for this approach is that it 
will simplify the complexity of the cancer proteome as 
all the proteins will be cleaved into smaller peptides 
and fractionated, and then the identity of the proteins 
present in the sample is revealed either according to 
their sequence or to their m/z spectra through pep-
tide mass fingerprinting (PMF).  
Urine is considered a specific filtrate of blood; 
the protein components of urine are qualitatively 
similar to those of blood but quantitatively more di-
luted (22). Generally, it contains highly soluble pro-
teins and peptides of low molecular weight (<30 kDa) 
which facilitate analyzing such polypeptides in their 
natural state (23). An advantage for urine over blood 
is that urinary polypeptides are stable and do not 
undergo significant proteolysis within several hours 
of collection in contrast to blood, where activation of 
proteases and generation of proteolytic breakdown 
products takes place within minutes of collection (24). 
Urinary proteomics presents an attractive approach to 
cancer biomarker discovery, not only for kidney/ 
urological malignancies (25, 26) but for other systemic 
malignancies (27, 28).Urinary biomarkers offer a great 
chance for the development of novel, non-invasive 
assays for the diagnosis, monitoring and the accurate 
diagnosis of Pca. Many advantages favor the use of 
urine for cancer biomarker discovery over blood and 
tissues samples, including the fact that urine-based 
tests are absolutely noninvasive, and urine is nonin-
fectious for HIV and less infectious for many other 
pathogens (29).  
In this study, we compared the urinary proteo-
mic profile of 8 PCa patients, 12 BPH patients and 10 
healthy males. Shotgun proteomics “bottom-up ap-
proach” was used to identify unique differentially 
expressed urinary proteins by pooling urine samples 
from each group. Two proteins (Fibronectin, and 
TP53INP2) were found to be de-regulated in both PCa 
and BPH patients. We evaluated the deregulation of 
these two proteins as potential non-invasive urinary 
biomarkers for the accurate diagnosis of prostate 
cancer among Benign Prostatic Hyperplasia Patients. 
Materials and Methods 
Urine sample collection.  
After approval from the Research Ethics Board at 
Brock University (St. Catharines, ON, Canada), urine 
samples were collected from 30 Egyptian males pre-
sent at Alexandria University’s General Hospital 
(Alexandria, Egypt). Urine samples were collected 
into 50mL Corning tubes containing Norgen’s Urine 
Preservative Solution (Cat# 18126) (Norgen Biotek, 
Thorold, ON, Canada). The samples were acquired 
from among three groups of individuals, each de-
scribed by a questionnaire completed by the patients’ 
attending physician. Group I urine samples were col-
lected from eight individuals diagnosed with Prostate 
Cancer (PCa). Group II urine samples were collected 
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from twelve individuals with Benign Prostatic Hy-
perplasia (BPH). Urine samples from Group III were 
collected from ten healthy males (Table 1). Urine 
samples collected from men with other ailments, in-
cluding Diabetes mellitus, kidney disease, and/or 
infections such as chronic HBV, HBV/HCV 
co-infection or Schistosomiasis, were excluded from 
participation. Each man included in the study was 
also given a PSA test as part of sample collection. 
Furthermore, urine samples were collected from the 
same patients two years from their initial participa-
tion in the study; a PSA test was also performed for 
this second collection. 
 
Table 1. Clinical parameters regarding the males involved with 
this study 
 Healthy 
Males 
Prostate 
Cancer Pa-
tients 
Benign Prostatic 
Hyperplasia Pa-
tients 
Number of males 10 8 12 
PSA Level (ng/mL) (0.8 ± 0.6) (7.9 ± 3.0) (4.9 ± 1.4) 
HCV or HBV Status -Ve -Ve -Ve 
Diabetes mellitus -Ve -Ve -Ve 
Schistosomiasis -Ve -Ve -Ve 
Kidney diseases -Ve -Ve -Ve 
 
 
Isolation of total proteins from urine.  
Total proteins were isolated from 1mL of urine 
using the Urine Protein Concentration Micro Kit 
(Cat# 17400) (Norgen Biotek, Thorold, ON, Canada). 
The isolation was performed according to the manu-
facturer’s instructions.  
Isolation of total RNA from urine.  
Total RNA was isolated from 2.5mL of urine 
using the Urine Total RNA Purification Maxi Kit 
(Slurry Format) (Cat# 29600) (Norgen Biotek, 
Thorold, ON, Canada). The isolation was performed 
according to the manufacturer’s instructions. 
Profiling of Pooled Urinary Proteins by 
LC-MS/MS.  
Before analysis, pooled protein samples were 
first digested in 25mM ammonium bicarbonate, using 
0.1μg of trypsin in a total volume of 50μL. After an 
overnight incubation at 37°C, the peptide solution 
was then lyophilized by SpeedVac centrifugation and 
subsequently re-suspended in 20μL of 0.1%TFA 
(Tri-Fluoro Acetic Acid). The LC/MS-MS experiment 
was performed at Sick-Kids Hospital (Proteomics Fa-
cility, Toronto, ON, Canada) using an on-line 
LC-MS/MS setup that employed an Agilent 1100 ca-
pillary liquid chromatography system (Palo Alto, CA, 
USA) that was fitted to an LTQ ion trap mass spec-
trometer (Thermo Electron, San Jose, CA, USA). A 
Carbon-18 pre-column (150µm i.d. x 5.0cm length) 
and a µLC analytical column (75µm x 10cm), which 
also served as a µESI emitter, were used for the sepa-
ration of the digested proteins.  
The samples were first injected into the 
pre-column for de-salting and then eluted into the 
analytical column for further separation. For the re-
verse-phase chromatography (C-18 column), a 60 
minute gradient elution from water to acetonitrile, 
and always containing 0.1% TFA, was performed at a 
flow rate of 0.2~0.3μL/min. The mass spectrometer 
was set to data-dependent mode, which automatically 
cycled through the acquisition of full-scan mass spec-
trums. Six further spectra were then sequentially rec-
orded on the six most abundant ions present upon the 
initial scan. A dynamic exclusion time of 90 seconds 
was used throughout.  
The LC-MS/MS data were initially obtained in 
*.RAW format, which were then converted into 
mzXML, basically a list of mass peaks. The lists were 
then used as input in a search of the human NCBI-NR 
database using the GPM XE (www.thegpm.org) 
search tool. Search results were then assessed in 
Scaffold (www.proteomesoftware.com). Acquired 
MS/MS data was also compared against three other 
databases: NCBI’s non-redundant database, Swis-
sProt and the MDSB database, all using the Mascot 
search tool (Matrix Science, London, UK). 
Relative expression profiling for candidate 
proteins using RT-qPCR.  
Relative mRNA expression levels for the 3 
candidate proteins (Cadherin 1, Fibronectin, and 
TP53INP2), determined from the shotgun proteomic 
analysis were analyzed among the PCa group, BPH 
group and the health male group. Candidate proteins 
were reversibly-transcribed using a 3 µl RNA 
template and 0.5 µl 0.5μg/μL Oligo (dT)18 Primer. 
The reaction was then made up with RNase-free 
water to 10μL then incubated for 5 mins at 70°C then 
held at 4°C. During the 4°C incubation, a mix of 4µl 5X 
first strand Buffer, 2µl of 0.1mM DTT, 1µl of 10mM 
dNTPs, 0.5µl SuperScript III (Invitrogen) and 2.5µl 
nuclease-free water were added to the initial reaction 
for a final reaction volume of 20µL. The final reaction 
was then incubated at 25°C for 5 min, 50°C for 30 min, 
70°C for 15 min with a final hold at 4°C. All samples 
were analyzed using the iCycler iQ real time PCR 
detection system with iQ SYBR Green Supermix 
(BioRad Laboratories, Mississauga, ON, Canada). For 
each sample, 3μl from its corresponding RT reaction 
were mixed in a 10μl iQ SYBR Green Supermix, 6.76μl 
nuclease-free water and 0.12μl Cadherin 1 (F) 5’- 
AAGAAGCTGGCTGACATGTACGGA -3’, Cadherin 
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1 (R) 5’- CCACCAGCAACGTGATTTCTGCAT -3’/ 
Fibronectin (F) 5’- AAACTTGCATCTGGAGGCAAA
CCC -3’, Fibronectin (R) 5’- AGCTCTGATCAGCATG
GACCACTT -3’/ TP53INP2 (F) 5’- AGGCCCTGAAA
TCTGAAGGGCTTA -3’ and TP53INP2 (R) 5’- 
AGTTCTAGCACCTTGGGCTTGTGA -3’ in a total of 
15μl reaction. All RT-qPCR experiments were carried 
out in triplicate and the expression levels were 
normalized to 5S rRNA levels. The relative expression 
level (fold change) for each candidate miRNA within 
each group was then calculated using the equation 
2-∆Ct test / 2-∆Ct control.  
Results 
LC-MS/MS Shotgun Analysis 
Liquid Chromatography coupled with tandem 
Mass Spectrometry (LC-MS/MS) analysis of the pro-
teins pooled from the healthy male group, the PCa 
group and the BPH group resulted in 2062, 1514 and 
2527 spectra for each of the respective samples. By 
analyzing the different spectra generated by the 
HPLC-MS/MS analysis with MASCOT, X! Tandem 
on-line search engines and the Scaffold proteome 
software, a total of 28 individual proteins in the 
healthy control sample, 41 in the BPH and 31 in the 
PCa sample were identified. Proteins were then clas-
sified based on the likelihood of their presence within 
each of the three-pooled samples. Of the identified 
proteins, 10 were common to all three groups: uro-
modulin, variants of Alpha-1 anti-trypsin, Al-
pha-2-glycoprotein-1, Ig lambda chain V region, Im-
munoglobulin light chain constant region, Fibrinogen 
gamma chain, Glutaminyl-peptide cyclotransferase, 
Hemopexin, Human Ferritin L Chain and Leu-
cine-rich α-2-glycoprotein-1 
Furthermore, there were sixteen proteins unique 
to the PCa group: Human Serum Albumin Com-
plexed with Myristate and Aspirin; Apolipopro-
tein-D; Prostaglandin H2 D-isomerase; Ig A1 Bur; 
G-protein coupled receptor 115; Cadherin-1; 
α-N-acetylglucosaminidase; Pro-epidermal growth 
factor; Apolipoprotein-J precursor; Human Be-
ta-Defensin-1; Matrilin-4; CD14 antigen; Chemo-
kine-like factor superfamily-5 isoform a; Fibronectin 
precursor; Immunoglobulin-kappa light chain varia-
ble region; and SLURP1. Another sixteen proteins 
were found to be unique to the BPH group, they were: 
α-1-microglobulin/bikunin pre-pro-protein; α-1 acid 
glycoprotein-2 precursor; Pepsinogen-3; Kininogen-1; 
Phosphoinositide-3-kinase interacting protein-1; Im-
munoglobulin heavy chain; Coagulation factor-II 
(thrombin); IgA-H; Amylase; Apolipoprotein-H; 
VASN protein; CD44 molecule; Protein-C inhibitor; 
EPH receptor B3; CD59 antigen pre-pro-protein; and 
Vitronectin. Ten proteins were identified in both the 
BPH and control groups and were notably absent 
from the PCa group, they were: hCG-1996769; com-
plement component-3 precursor; retinol binding pro-
tein-4; myosin VA; haptoglobin; keratin-13; defensin 
HNP1; delta-globin; PRO-2675; and hCG-1817845 
There were eight proteins found in the control 
group that were notably missing from both the PCa 
and BPH samples, they were: Lipopolysaccharide 
binding protein; Janus kinase and microtubule inter-
acting protein-2; Polyamine modulated factor-1 
binding protein-1; α-mannosidase-II; Apolipopro-
tein-A-I; Zinc finger protein; ACSF3 protein; and 
Chloride intracellular channel-1. Another five pro-
teins were absent from the control sample but were 
present in both the pooled PCa and BPH samples, 
they were: Apo-Human Serum Transferrin 
(Non-Glycosylated); Nidogen 1 precursor; 
N-ethylmaleimide-sensitive factor attachment pro-
tein; CTCL tumour antigen; and Tumour Protein 53 
Inducible Nuclear Protein 2 (TP53INP2).  
Determining the Expression of Cadherin-1, 
Fibronectin and TP53INP2 mRNA among in-
dividual Prostate Cancer samples by RT-qPCR 
Employing RT-qPCR, mRNA levels among in-
dividual samples were compared to the average ex-
pression levels of the healthy control group. Tran-
script expression for each sample was first normalized 
against the sample’s own content of 5S rRNA. Rela-
tive expression was then calculated as LOG2 fold 
change values according to equation: LOG2 (2-∆Ct (target 
mRNA) PCa / 2-∆Ct (target mRNA) Mean Healthy Control) 
(Table 2). 
 
Table 2. LOG2 fold change values for the expression of: Cad-
herin-1, Fibronectin and TP53INP2 mRNAs among initially col-
lected PCa samples.  
  LOG2 Fold Change (PCa / Average Healthy Control) 
Sample ID Cadherin-1 Fibronectin TP53INP2 
PCa 1 4.91 -4.24 -9.36 
PCa 2 -7.39 -0.04 -14.76 
PCa 3 -4.39 -10.14 -23.86 
PCa 4 -1.49 -2.94 0.34 
PCa 5 -6.69 -7.14 -4.76 
PCa 6 -1.09 -2.44 -0.96 
PCa 7 N/A -2.64 0.04 
PCa 8 0.81 -6.84 0.24 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated 
and Black – Minimally Deregulated) (Relative to average healthy group expression) 
 
 
In contrast to mass spectrometry data that 
showed Cadherin-1, Fibronectin and TP53INP2 pro-
teins to be present in the pooled PCa sample and not 
in the healthy control sample, mRNA levels for the 
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corresponding proteins (especially Fibronectin and 
TP53INP2) were widely down-regulated amongst 
individual PCa samples. In particular, Fibronectin 
mRNA was found to be down-regulated in seven of 
the eight PCa samples. TP53INP2 mRNA was found 
to be down-regulated in half of PCa samples. Cad-
herin-1 mRNA on the other hand was found to be 
up-regulated in one sample, unchanged in one and 
down-regulated in the remaining five PCa. Figure 1 
illustrates the percentage of initially collected PCa 
samples with either up, down or minimal deregula-
tion, for each of the three target mRNAs. 
Screening for Deregulation of Fibronectin and 
TP53INP2 among BPH Samples by RT-qPCR 
Since both Fibronectin and Cadherin-1 proteins 
were specifically identified by mass spectrometry in 
the pooled PCa sample, but only Fibronectin mRNA 
(and not Cadherin-1 mRNA) was consistently 
down-regulated among initially collected PCa sam-
ples it was decided that only Fibronectin mRNA ex-
pression would be evaluated in the initially collected 
BPH samples. Analysis then revealed that Fibronectin 
mRNA was variably expressed in BPH, 
down-regulated in eight of the twelve initially col-
lected BPH samples (67%), unchanged in one (8%) 
and up-regulated in three (25%) (Table 3). 
Since the TP53INP2 protein was originally iden-
tified by mass spectrometry in both PCa and BPH, 
and since its mRNA was considerably 
down-regulated in half the PCa samples, its expres-
sion was also evaluated among individual BPH sam-
ples. Expression analysis among the initially collected 
BPH samples revealed that TP53INP2 mRNA was 
predominantly down-regulated. TP53INP2 mRNA 
was down-regulated in ten of the twelve samples 
(83%) (Table 3). Figure 2 illustrates the percentage of 
initially collected BPH samples with either up, down 
or minimal deregulation, for both Fibronectin and 
TP53INP2 mRNA. 
 
 
Figure 1. Percentage of initially collected PCa samples with either up, down or minimal deregulation in the expression of mRNAs for: Cadherin-1, 
Fibronectin or TP53INP2. 
 
 
 
Figure 2. Percentage of initially collected BPH samples with up, down or minimal deregulation in the expression of mRNAs for: Fibronectin or TP53INP2. 
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Table 3. LOG2 fold change values for the expression of: Fi-
bronectin and TP53INP2 mRNAs among initially collected BPH 
samples.  
 LOG2 Fold Change (BPH / Average Healthy Control) 
Sample ID Fibronectin TP53INP2 
BPH1 -5.14 -0.96 
BPH2 -5.04 -21.36 
BPH3 -6.34 -16.56 
BPH4 -2.94 -1.96 
BPH5 3.06 -12.86 
BPH6 -2.14 -3.26 
BPH7 -6.24 -21.76 
BPH8 -6.74 -6.56 
BPH9 -0.54 N/A 
BPH10 1.26 -13.96 
BPH11 1.86 -12.06 
BPH12 -2.69 -10.56 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated 
and Black – Minimally Deregulated) (Relative to average healthy group expression) 
 
Re-evaluating Fibronectin and TP53INP2 
mRNA expression in PCa samples after two 
years 
Since both Fibronectin and TP53INP2 mRNA 
appeared to be down-regulated in at least half of the 
initially collected, PCa and BPH samples, it was de-
cided to re-evaluate expression levels for the PCa 
samples as part of the two year follow-up. Expression 
levels were again determined by RT-qPCR, on RNA 
isolated from urine samples collected two years sub-
sequent to the initial collection. For every sample, 
both transcripts were normalized against the sample’s 
own content of 5S rRNA. Differential expression was 
then determined by comparing expression against the 
average healthy group’s level. Relative expression 
was then calculated as LOG2 fold change values ac-
cording to the equation: LOG2 (2-∆Ct (target mRNA) 
PCa / 2-∆Ct (target mRNA) Mean Healthy Control) 
(Table 4).  
Analysis revealed that both Fibronectin and 
TP53INP2 mRNA were down-regulated in six of the 
eight PCa samples (75%). For Fibronectin mRNA this 
was a drop from the seven out of eight samples ob-
served previously to be down-regulated (Figure 3). 
Interestingly however, despite this drop in frequency 
(of down-regulation), after two years many of the 
same PCa samples (PCa 3, 5, 6, 7, 8) had maintained 
their initially observed down-regulation of Fibron-
ectin mRNA. Only PCa samples 1 and 4 had changed, 
becoming up-regulated or unchanged (respectively) 
with respect to the mean level of the original healthy 
control group. For TP53INP2 mRNA levels, 
down-regulation was more frequent after two years 
(75% versus 50%), occurring in three additional sam-
ples, PCa 4, 6 and 8. Meanwhile some of the other 
patients (PCa 1, 2, 5) maintained their 
down-regulation in TP53INP2 mRNA.  
 
Table 4. LOG2 fold change values for the expression of: Fi-
bronectin and TP53INP2 mRNAs among PCa samples collected 
after two years.  
 LOG2 Fold Change (PCa / Average Healthy Control) 
Sample ID Fibronectin TP53INP2 
PCa 1 1.66 -7.66 
PCa 2 -5.24 -4.66 
PCa 3 -2.54 N/A 
PCa 4 -0.54 -13.46 
PCa 5 -2.74 -2.36 
PCa 6 -1.34 -18.86 
PCa 7 -7.34 N/A 
PCa 8 -1.14 -6.86 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated 
and Black – Minimally Deregulated) (Relative to average healthy group expression) 
 
 
 
Figure 3. Percentage of PCa samples with down-deregulation in the expression of mRNAs for: Fibronectin or TP53INP2. (Determined by RT-qPCR) 
 
Initial Collection
Initial Collection
After 2 Years After 2 Years
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Re-evaluating Fibronectin and TP53INP2 
mRNA expression in BPH samples after two 
years 
Since deregulation of either Fibronectin or 
TP53INP2 appeared to be common in PCa and BPH 
samples, even after two years, it was decided to 
re-evaluate their expression levels in the BPH samples 
that were collected after two years. It should be noted 
that of the original twelve BPH patients, only eight 
were successfully located for follow-up testing; of the 
eight, four happened to be diagnosed with PCa at this 
point (BPH patients 1, 9, 10 and 11).  
Expression analysis by RT-qPCR revealed that 
Fibronectin mRNA was now down-regulated in only 
two of the eight BPH samples (25%), down from the 
previous 67% (Figure 4). Interestingly, two of the four 
BPH patients who were found to have PCa at the se-
cond diagnosis, did in fact have down-regulation of 
Fibronectin mRNA in their urine after two years. The 
first, BPH 1, had shown such deregulation as early as 
two years prior, during the initial collection; BPH 10 
on the other hand went from Fibronectin being 2.4 
fold up-regulated to 4.7 fold down-regulated after 
two years (Table 5). TP53INP2 mRNA expression was, 
after two years found to be at least two fold 
down-regulated in seven of the eight BPH samples 
(88%) versus ten out of twelve previously (83%), a 
roughly consistent fraction. 
 
Table 5. LOG2 fold change values for the expression of: Fi-
bronectin and TP53INP2 mRNAs among BPH samples collected 
after two years.  
 LOG2 Fold Change (BPH / Average Healthy Control) 
Sample ID Fibronectin TP53INP2 
BPH1 -5.34 -4.36 
BPH4 4.16 -1.36 
BPH6 3.06 -3.36 
BPH7 0.56 -9.76 
BPH9 -0.74 -8.36 
BPH10 -2.24 N/A 
BPH11 0.06 -13.86 
BPH 12 1.96 -14.06 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated 
and Black – Minimally Deregulated) (Relative to average healthy group expression) 
 
 
 
Figure 4. Percentage of BPH samples with down-deregulation in the expression of mRNAs for: Fibronectin or TP53INP2 
 
 
Diagnostic Utility of Fibronectin & TP53INP2 
for Diagnosing Prostate Cancer  
To evaluate the potential for using the aberrant 
expression of Fibronectin or TP53INP2 mRNA for 
diagnosing PCa, the medical records, specifically PSA 
values and clinical diagnoses for all BPH patients 
were updated as part of the two-year follow-up. It 
should be noted that all BPH patients were therefore 
diagnosed twice, once initially and then again after 
two years. Interestingly, during the second assess-
ment it was discovered that four of the BPH patients 
in fact had PCa, they were: BPH 1, 9, 10 and 11 (Table 
6).  
By comparing putative diagnoses (of PCa) made 
using mRNA deregulation against the actual clinical 
diagnoses, the sensitivity and specificity for using at 
least two fold down-regulation of Fibronectin and 
TP53INP2 (separately or in tandem) for diagnosing 
PCa were determined. The following criteria were 
applied: patients with a positive clinical diagnosis and 
exhibiting down-regulation of either Fibronectin or 
TP53INP2 or deregulation of both, were considered 
true positives; patients with a positive clinical diag-
nosis and not exhibiting down-regulation of either 
gene (either separately) or only one gene (in tandem) 
were considered false negatives; patients with a neg-
ative clinical diagnosis and exhibiting 
Initial Collection
Initial Collection
After 2 Years
After 2 Years
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down-regulation of either Fibronectin or TP53INP2 or 
deregulation of both, were considered false positives; 
and patients with a negative clinical diagnosis and not 
exhibiting down-regulation of Fibronectin or 
TP53INP2 or exhibiting down-regulation of only one 
or neither (when combined), were considered true 
negatives. 
By applying the above-mentioned criteria, both 
sensitivity and specificity for using down-regulation 
in Fibronectin and/or TP53INP2 for diagnosing PCa 
were determined. Using Fibronectin mRNA 
down-regulation on its own to diagnose PCa resulted 
in a sensitivity of 75% and a specificity of 50%, while 
using TP53INP2 mRNA down-regulation on its own 
to diagnose PCa resulted in a sensitivity of 76% and 
specificity of 7%. Furthermore, the sensitivity and 
specificity for using the tandem down-regulation of 
both genes for diagnosing PCa was 47% and 53%, 
respectively. The sensitivity and specificity for a panel 
employing down-regulation of both genes and an 
elevated serum PSA (≥4ng/mL) for detecting PCa was 
35% and 73%, respectively. Table 7 summarizes the 
sensitivity and specificity values for the various as-
says. 
 
Table 6. Diagnosing PCa among BPH Patients by Assessing Deregulation of Fibronectin and TP53INP2 mRNA. 
Sample ID Initial Urine Collection Urine Collection After 2 Years 
LOG2 Fold Change (BPH / Avg 
Control) 
Clinical Diag-
nosis for PCa 
Serum PSA 
Levels 
(ng/mL) 
LOG2 Fold Change (BPH / Avg 
Control) 
Clinical Diag-
nosis for PCa 
Serum PSA 
Levels 
(ng/mL) Fibronectin TP53INP2 Fibronectin TP53INP2 
BPH1 PCa Healthy Healthy 4.3 PCa PCa PCa 3.9 
BPH2 PCa PCa Healthy 5.6 N/A N/A N/A N/A 
BPH3 PCa PCa Healthy 3.9 N/A N/A N/A N/A 
BPH4 PCa PCa Healthy 5.8 Healthy PCa Healthy 9.6 
BPH5 Healthy PCa Healthy 2.4 N/A N/A N/A N/A 
BPH6 PCa PCa Healthy 5.1 Healthy PCa Healthy 4.8 
BPH7 PCa PCa Healthy 6.9 Healthy PCa Healthy 4.2 
BPH8 PCa PCa Healthy 3.7 N/A N/A N/A N/A 
BPH9 Healthy N/A Healthy 4.3 Healthy PCa PCa 10.5 
BPH10 Healthy PCa Healthy 5.1 PCa N/A PCa 9.8 
BPH11 Healthy PCa Healthy 7.4 Healthy PCa PCa 4.2 
BPH12 Healthy PCa Healthy 3.8 Healthy PCa Healthy 9.4 
 
 
Table 7. Diagnostic Utility of Fibronectin and TP53INP2 for 
Diagnosing PCa. 
Candidate Biomarker(s) Sensitivity (%) Specificity (%) 
Fibronectin 75 50 
TP53INP2 76 7 
Fibronectin/TP53INP2 47 53 
Fibronectin/TP53INP2/PSA 35 73 
 
Discussion 
Proteomics studies are useful for identifying 
cancer biomarkers. Traditional techniques such as 
two-dimensional gel electrophoresis have typically 
been used for this purpose - in one instance to identify 
proteins uniquely expressed by androgen stimulation 
of PCa cells (30). In contrast, more modern proteomics 
studies rely on either protein microarray or mass 
spectrometry to identify specific proteins; both of 
which have also been successfully employed towards 
the study of cancer, including PCa (31). Nonetheless, 
the number of successful high-throughput studies 
that have assessed proteins, especially from the urine 
of patients with PCa and/or BPH has been minimal 
(32). Therefore in this study, urinary proteins were 
evaluated by liquid chromatography coupled to tan-
dem mass spectrometry to identify promising protein 
candidates for a PCa biomarker. 
In order to identify those proteins and others 
that were differentially expressed between the 
groups, a “bottom-up” shotgun-based analysis using 
LC-MS/MS was employed. Proteins, pooled into 
three samples (PCa, BPH and Control) were analyzed 
using LC-MS/MS to reveal 1514, 2527, 2062 respective 
spectra. From these spectra, a total of 31 proteins were 
identified in the PCa sample, 41 in the BPH and 28 in 
the control. One protein, Tamm-Horsfall Protein 
(Uromodulin), was common to all three groups. 
Uromodulin is one of the most abundant proteins in 
urine (33, 34, 35) and normally runs as a monomer 
around 68kDa on denaturing gels. It is therefore likely 
that uromodulin, at least in part, formed the band that 
was observed near 66kDa in many of the samples 
from this study. Some authors have suggested that 
depleting abundant proteins before profiling might 
help to elucidate rare proteins that can be masked by 
the presence of proteins in such high abundance (36, 
37). Unfortunately depleting highly abundant pro-
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teins, which can act as transporters or carriers of other 
macromolecules, can also lead to the loss of other po-
tentially important proteins (38). 
Importantly, pooled analysis identified at least 
two proteins, found only in the cancer sample, that 
are acknowledged in the literature as potentially be-
ing involved with cancer: Cadherin-1 (E-Cadherin) 
and Fibronectin precursor proteins. In many cancers, 
the down-regulation or complete loss of E-Cadherin is 
reported to correlate to tumour malignancy (39). Lack 
of E-Cadherin, an epithelial glycoprotein, which me-
diates cell-cell adhesion (40), has even been associated 
with a poor prognosis in PCa patients (41, 42). Fur-
thermore, a decrease in E-Cadherin expression has 
been associated with an invasive and metastatic 
phenotype, also in PCa (42, 43, 44). In light of its po-
tential contribution to the development and progres-
sion of PCa, and to assess its utility as a candidate 
biomarker for PCa, Cadherin-1 was selected for fur-
ther evaluation among individual urine samples. 
Fibronectin, another protein identified via 
pooled analysis, is normally present in the Extracel-
lular Matrix (ECM) (45). ECM normally also contains 
adhesion molecules such as laminins, fibronectins, 
glycoproteins, chondroitins, heparin sulfate, colla-
gens, tenascins, proteoglycans, etc. that together 
complete a complex network that forms the basis of 
connective tissues. Furthermore these molecules are 
typically produced locally and by cells that are adja-
cent to the ECM (45). The ECM serves a diverse role, 
aiding in anything from the regulation of cellular dif-
ferentiation to migration, tissue remodeling and even 
helping to maintain tissue integrity (46). The ECM 
and its components have also been shown to play an 
important role during invasion and metastasis of ma-
lignant cells throughout the body (46). Normally it is 
integrins (cell membrane protein) that connect cells, 
including prostatic epithelial cells, to the ECM by 
binding to fibronectin already present in the matrix 
(47). This interaction is required for proper assembly 
of fibronectin in the matrix, something that is very 
important for ECM organization and stability (48, 49). 
Cancer typically involves an epithelial to mesenchy-
mal transition (EMT), whereby malignant cells can 
now break loose of their defined position within the 
microenvironment. This is usually associated with the 
loss of E-Cadherin and disruption of local ECM (50). 
To do this, cells not only decrease expression of 
E-Cadherin but also reduce their expression of integ-
rins, and alter their secretion of ECM components; 
something that has been shown to occur in invasive 
PCas (51, 52). It has also been reported that in poorly 
differentiated PCas, the expression of Fibronectin is 
significantly reduced, thereby weakening the ECM 
itself (53). Loss or significant down-regulation of Fi-
bronectin has therefore been proposed as a mecha-
nism for cancer’s malignant nature, whereby cancer 
cells are more readily able to detach from a tumour 
mass before spreading elsewhere (54). In light of Fi-
bronectin’s role in cancer progression particularly 
with regards to published observations made in PCa, 
and since it was identified only in the pooled PCa 
sample (as assessed by mass spectrometry), Fibron-
ectin was selected for further analysis (to assess its 
candidacy as a potential biomarker for PCa) among 
the individual urine samples collected during this 
study. 
Another protein, tumour protein-53 induced 
nuclear protein-2 (TP53INP2), was notably absent 
from the pooled control but present among both the 
pooled BPH and PCa samples. TP53INP2 is thought to 
be a scaffold protein that is normally expressed upon 
induction by the p53 tumour suppressor protein (55). 
TP53INP2 is required for proper autophagy (56) a 
process that occurs when a cell recycles old materials 
by engulphing them into a lipid membrane and then 
fusing said membrane with lysosomes, ultimately 
catabolizing the contents (57). Autophagy is also 
known to occur during programmed cell death (58); 
one of the responses p53 is known to regulate (58). 
Importantly TP53INP2 is thought to possess tumour 
suppressor-like functionality, which might help ex-
plain why in pre- and neoplastic cervical cancers it is 
the target of various microRNAs that block its ex-
pression (59). Possibly as a result of the same mecha-
nism, it was observed that in some instances of colo-
rectal cancer p53 was unable to induce expression of 
TP53INP2 (60). TP53INP2 has also been observed at 
unusually low levels in some PCas (61). Furthermore, 
in a PCa cell line (LNCaP) the drug Genistein, nor-
mally used to treat PCa, was shown to up-regulate 
TP53INP2, among other genes (62). Moreover, it has 
also been proposed that the occurrence of a specific 
splice variant of TP53INP2 might be a necessary event 
in order for malignant cells to invade the ECM (63). 
Finally, in 2007 a patent was filed that described using 
measurements of TP53INP2, among other targets, as 
part of a multivariate signature to monitor the pro-
gression of PCa (64). Therefore based on TP53INP2’s 
potential role in cancer, and because it was commonly 
identified in both pooled PCa and BPH samples, it 
was selected for analysis among individual samples to 
assess its candidacy as a potential PCa biomarker. 
Based on the aforementioned evidence regarding 
the selected proteins (Cadherin-1, Fibronectin, 
TP53INP2) and their probable involvement in the 
development or progression of malignancy, their 
utility towards diagnosing PCa was investigated. The 
expression level of the selected candidate’s mRNA 
(Cadherin-1, Fibronectin and TP53INP2) was assessed 
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on a sample-by-sample basis via RT-qPCR. The first 
candidate that was investigated by RT-qPCR was 
Cadherin-1. Initially observed only in pooled PCa by 
mass spectrometry, Cadherin-1 mRNA was later 
found to be down-regulated (relative to the average of 
the healthy group), among a majority of the initially 
collected PCa samples (63%), but remained un-
changed in 13% and even up-regulated in 13%. As-
suming elevated levels of mRNA correlate to elevated 
levels of protein, then an up-regulation of Cadherin-1 
mRNA in just one patient would explain why it was 
observed at all in the mass spectrometry data for 
pooled PCa proteins. A down-regulation of Cadher-
in-1 is reported in the literature to correlate with gen-
eral tumour invasiveness (39). Down-regulation has 
also been associated with metastases in PCa and is 
therefore (as was shown in the literature), an indicator 
of poor prognosis among PCa patients (42). Since 
down-regulation of Cadherin-1 is likely a prognostic, 
as opposed to diagnostic factor and because it was not 
strictly down-regulated in a strong majority of cancer 
patients, it was considered a second-rate candidate for 
future testing. 
As for Fibronectin, differential expression pro-
filing of its mRNA transcript among initially collected 
PCa samples revealed down-regulation across 88% of 
samples and up-regulation among none. The 
RT-qPCR data on Fibronectin mRNA expression 
would seem to agree with LC-MS/MS data suggest-
ing that at least one PCa patient presented with 
fragments of fibronectin in their urine. RT-qPCR data 
also complements a report in the literature suggesting 
that down-regulation or complete loss of Fibronectin 
can promote tumour invasiveness by allowing ma-
lignant cells to more easily detach from a tumour 
mass (54). Due to its putative role in cancer progres-
sion and because Fibronectin mRNA was deregulated 
among a large majority of samples and up-regulated 
among none, it was selected for further assessment 
among BPH samples. 
TP53INP2, reportedly down-regulated in PCa 
(51), was found in both PCa and BPH but interestingly 
not in control when pooled samples were assessed by 
LC-MS/MS. To investigate this trend, levels of 
TP53INP2 mRNA were assessed for differential ex-
pression in PCa samples by RT-qPCR. Unsurprising-
ly, TP53INP2 mRNA was down-regulated in 50% of 
the initially collected PCa samples and up-regulated 
in none of them. These results further agree with 
Poustka, who in 2007 proposed using the deregula-
tion of TP53INP2 as part of a multivariate signature to 
monitor progression in PCa patients. Due to 
TP53INP2’s likely role in PCa and because 
LC-MS/MS data alluded to its presence in the BPH 
cohort, some of whom were ultimately diagnosed 
with PCa, TP53INP2 was selected for further evalua-
tion among BPH patients. 
Since down-regulation of both Fibronectin and 
TP53INP2 were observed among a large percentage of 
the initially collected PCa samples and due to their 
literature suggested roles in cancer, the differential 
expression of Fibronectin and TP53INP2 mRNA was 
evaluated among BPH samples. Comparing Fibron-
ectin and TP53INP2 mRNA levels in the BPH samples 
to the average healthy group level revealed a 
down-regulation among a number of the BPH pa-
tients, some of whom were subsequently suspected of 
and then diagnosed with PCa (BPH1, BPH9, BPH10 
and BPH11). Furthermore, differential expression 
profiling of both transcripts in urine collected from 
the same patients (both PCa and BPH) after two years 
seemed to confirm the observations made initially. 
Since deregulation of Fibronectin and/or TP53INP2 
might have foreshadowed a diagnosis of PCa among 
some of the BPH patients, down-regulation in urine is 
tentatively proposed as an indicator for PCa that may 
ultimately be useful for diagnosing or differentiating 
PCa from BPH. 
In order to validate the diagnostic potential of 
Fibronectin and TP53INP2 mRNA deregulation for 
predicting PCa, medical records including PSA levels 
and clinical diagnoses were updated as part of a 
two-year follow-up. Both genes differed substantially 
in their ability to accurately detect PCa. At least 
two-fold down-regulation of Fibronectin mRNA 
showed the most potential for diagnosing PCa; it had 
a sensitivity of 75% and specificity of 50%. Fibronectin 
mRNA deregulation was often successful at identify-
ing PCa samples as positive, but slightly less suc-
cessful at designating patients with benign disease as 
negatives. Altogether, Fibronectin displayed a strong 
ability to predict PCa. The predictive nature of Fi-
bronectin deregulation might reflect its role in the 
ECM as an essential regulator of cellular differentia-
tion, migration, and tissue remodeling and integrity 
(46). Interestingly, using urinary Fibronectin mRNA 
down-regulation to predict PCa resulted in a more 
specific, albeit less sensitive test than traditional PSA 
testing which has a sensitivity and specificity of 86% 
and 33% at the FDA recommended threshold of 
≥4ng/mL of blood (65). The improvement in specific-
ity rises dramatically when compared to PSA at a 
cutoff of ≥2.5ng/mL (98.2% sensitivity and 16.6% 
specificity) (66). As for TP53INP2 on the other hand, 
its down-regulation was moderately sensitive (75%), 
identifying many patients with PCa, but was entirely 
non-specific (7%), designating many of the benign 
samples as malignant and being unable to accurately 
identify more than one negative. 
To improve the chances of accurately predicting 
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PCa, various combinations of the identified candi-
dates were evaluated. The sensitivity and specificity 
for combining both Fibronectin and TP53INP2 
down-regulation to detect PCa was 47% and 53%, 
respectively. Interestingly this combination success-
fully designated at least one of the malignant and 50% 
of benign samples within the updated BPH cohort; 
PSA on the other hand might have correctly desig-
nated 75% of those cancers but unfortunately would 
not have cleared any of the negatives.  
When both mRNA-based protein candidates 
were combined with PSA (cutoff ≥4ng/mL), specific-
ity was increased to 73%; at the same time sensitivity 
was reduced to 35%. Thus far the protein-based ap-
proach has identified at least one potential candidate 
that merits further study towards the accurate detec-
tion of PCa. And although these early results indicate 
a reasonable sensitivity and specificity, further studies 
must still be conducted using a larger pool of samples 
collected over a longer period of time both before and 
after disease has progressed, to validate their roles in 
PCa. Employing urine, like in this study, as the basis 
for a screening assay would be a convenient and 
non-invasive way to screen more men, and potentially 
reduce unnecessary biopsies by differentiating PCa 
from BPH, and if PCa is diagnosed earlier, possibly 
even reduce PCa mortality rates as well. 
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